DOCSLIB.ORG

Adverse Drug Reaction of the Month ACE Inhibitor Use and Severe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adverse Drug Reaction of the Month ACE Inhibitor Use and Severe Postgrad MedJ 1998;74:571-572 C The Fellowship of Postgraduate Medicine, 1998 Adverse drug reaction of the month Postgrad Med J: first published as 10.1136/pgmj.74.875.571 on 1 September 1998. Downloaded from ACE inhibitor use and severe angioedema A Murray, J Crowther The prescribing of angiotensin-converting en- arrangements for tracheostomy were made, as zyme (ACE) inhibitors in the management of no clear airway could be identified on fibre- hypertension and cardiac failure has increased optic examination. This was performed under greatly since their introduction in the 1980s. local anaesthetic. Medical treatment was con- Generally, these drugs are considered safe,' 2 tinued for 48 hours. The patient had been tak- but they are known to precipitate angioedema ing enalapril for 6 months and this was discon- as a side-effect, with an incidence of tinued. She has had no further episodes of 0. 1-0.2%.2 Angioedema is a non-pitting, ery- angioedema, after 6 months. Twice prior to thematous oedema in the skin and subcutane- admission the patient had been aware of her ous tissues, which is well-defined and results in tongue being swollen, but had not sought rapid, and often profound, soft tissue swelling advice. C 1 esterase inhibitor levels were which may be life-threatening, as the head and normal. neck region is almost always affected.2 4 The numbers of reported cases of this association Case 3 are increasing as usage of this group of drugs A 71-year-old man was admitted to the Ear, increases and it is now the most frequently Nose & Throat ward with swelling of the floor identified cause in patients admitted with of his mouth. He was taking trandolopril 4 mg angioedema.2-10 (an ACE inhibitor) as part of a clinical study in essential hypertension, and had been for the Case reports previous two years. A fibre-optic examination revealed no airway involvement. He had expe- Case 1 rienced minor episodes of angioedema over the A 73-year-old hypertensive woman presented preceding 8 months, including one admission to Accident and Emergency (A&E) with to hospital. His C1 esterase inhibitor levels left-sided tongue swelling. She had had many were normal. The ACE inhibitor was stopped. episodes of angioedema over the previous 3 Due to worsening cardiac function, though, the years, once requiring admission, and carried man was recommenced on ACE inhibitors by a her own injectable adrenaline, though the rea- cardiologist (ramipril 2.5 mg). He has reported son for her angioedema had not been identi- to the dermatology clinic that he has had a fied. She had been taking lisinopril 2.5 mg for recurrence of his angioedema. We have since 3.5 years. She was admitted and given that an alternative to an ACE recommended http://pmj.bmj.com/ intravenous chlorpheniramine 10 mg and inhibitor is used. hydrocortisone 200 mg. Her airway was satisfactory on fibre-optic examination. Over Discussion the next 2 hours she became stridulous. Repeat examination showed the base ofher tongue and Angioedema in ACE inhibitor users is a rare supraglottis to be swollen. Arrangements were complication, although it is acknowledged in made for her airway to be secured and repeat the Summaries ofproduct characteristics of ACE intravenous chlorpheniramine 10 mg, hydro- inhibitors. The symptoms are frequently mild on October 5, 2021 by guest. Protected copyright. cortisone 200 mg, and intramuscular adrena- and self-limiting2A and the episodes often occur line 1 mg were administered. Within 20 upon the commencement of treatment, al- minutes the patient's condition had dramati- though delays of months and even years have cally improved and intubation/tracheostomy been reported.5 6 was averted. A further fibre-optic examination The mechanism for ACE inhibitors to revealed much less oedema. Medical treatment produce angioedema is not clear but is was continued over the next 48 hours. The probably through a tissue accumulation of Department of patient had been previously assessed for bradykinin which is a potent vasodilator, as Otolaryngology, hereditary angioedema and had normal levels ACE is a bradykinin degrading (kininase) Victoria Infirmary, of C1 esterase inhibitor and complement. Her Glasgow G42 9TY, UK enzyme and the drugs inhibit this action.8 It is A Murray ACE inhibitor was stopped and she has had no also clear that different ACE inhibitors have J Crowther further episodes of angioedema in 6 months. slightly different structures, and possibly differ- ing levels of side-effects. For instance, captopril Correspondence to Mr A Case 2 induces tissue-specific auto-antibodies much Murray, Specialist Registrar in Otolaryngology, A 72-year-old woman with acute angioedema, more frequently than enalapril, though the sig- Department of also ofher tongue and supraglottis, was sent by nificance of this is uncertain.2 Present infor- Otolaryngology, Royal ambulance from her general practitioner to mation is not adequate to identify clearly Hospital for Sick Children, Yorkhill, Glasgow, UK A&E. Intravenous hydrocortisone 200 mg and whether or not the true incidences of an- chlorpheniramine 10 mg were administered, gioedema differ,3 and given the small percent- Accepted 16 December 1997 with intramuscular adrenaline 1 mg, and ages, a randomised controlled trial to answer 572 Adverse drug reactions this question would be difficult. It is obviously important, though, to notify the Committee on Learning points of of Safety Medicines, any possible drug reac- Postgrad Med J: first published as 10.1136/pgmj.74.875.571 on 1 September 1998. Downloaded from * in patients admitted to hospital with tions, even recognised ones, as was done with angioedema, ACE inhibitor usage is the most our patients, to allow possible patterns of side- frequently identified cause effects to be assessed. * it should therefore be the first diagnosis The differential diagnoses of angioedema considered by any clinician seeing a patient with includes upper respiratory, or dental, infec- angioedema * angioedema almost always affects the head and tions, epiglottitis, asthma or anaphylaxis but neck and therefore the airway is at risk the critical history of ACE inhibitor use must * angioedema is not an allergic reaction and can be elicited. If this is missed, and ACE inhibitor occur many months after starting an ACE use continues, further episodes of angioedema inhibitor may occur7 which may be life-threatening, as * patients with idiopathic angioedema should not receive ACE inhibitors, as their condition can happened in two of our patients. A further worsen critical point in the history is to ensure that patients previously suffering from idiopathic angioedema, are not commenced on ACE inhibitors, as this has clearly been shown to worsen the condition.'0 have been used to modify the reaction and Angioedema secondary to ACE inhibitors is intravenous fluids and oxygen may also be not an allergic reaction and so management needed. aimed solely at modifying the allergic response In spite of the increasing body of literature will not always be effective. Neither is there an available on this subject, doctors dealing with abnormality of the complement system, as in this emergency condition still appear to be hereditary angioedema, and C 1 esterase inhibi- unfamiliar with its features. The failure to tor and C4 fraction levels can be measured to change these patients' medication may be exclude this, where there is any doubt. exposing them to significant risk. Treatment requires that the airway is secured and subcutaneous or intramuscular adrenaline Keywords: angioedema; angiotensin-converting given. The ACE inhibitor is stopped. Steroids enzyme inhibitor; airway obstruction 1 Inman WHW, Rawson NSB, Wilton LV, Pearce GL, Speirs 6 Jain M, Armstrong L, Hall J. Predisposition to and late onset CJ Postmarketing surveillance of enalapril. 1 Results of of upper airway obstruction following angiotensin- prescription-event monitoring. BMJ 1988;297:826-9 converting enzyme inhibitor therapy (Review). Chest 1992; 2 Israili ZH, Hall WD. Cough and angioneurotic edema asso- 102:871-4. ciated with angiotensin-converting enzyme inhibitor 7 Finley CJ, Silverman MA, Nunez AE. Angiotensin- therapy: a review of the literature and pathophysiology. Ann converting enzyme inhibitor-induced angioedema: still Intern Med 1992;117:234-42. unrecognized. Am J Emerg Med 1992;10:550-2. 3 Slater EE, Merrill DD, Guess HA, et al. Clinical profile of 8 Jett JK. Captopril angioedema: first report. Ann Emerg Med angioedemaassociated with angiotensin converting enzyme 1 984;13:489-90. inhibition. JAMA 1988;260:967-70 9 Hedner T, Samuelsson 0, Lunde H, Lindholm L, Andren 4 Megerian CA, Arnold JE, Berger M. Angioedema: 5 years' L, Wiholm B. Angio-oedema in relation to treatment with experience, with a review of the disorder's presentation and angiotensin converting enzyme inhibitors. BMJ 1992;304: treatment. Laryngoscope 1992;102:256-60. 941-6. 5 Forslund T, Tolano H, Weckstrom G, Stenborg M, Jarvinen 10 Orfan N, Patterson R, Dykewicz MS. Severe angioedema http://pmj.bmj.com/ S. Angio-oedema induced by enalapril (Review). J Intern related to ACE inhibitors in patients with a history of idio- Med 1995;238:179-81. pathic angioedema. JAMA 1990;264:1287-9. on October 5, 2021 by guest. Protected copyright..
Load more

Recommended publications
  • Infection of the CNS by Scedosporium Apiospermum After Near Drowning
    205 CASE REPORT J Clin Pathol: first published as 10.1136/jcp.2003.8680 on 27 January 2004. Downloaded from Infection of the CNS by Scedosporium apiospermum after near drowning. Report of a fatal case and analysis of its confounding factors P A Kowacs, C E Soares Silvado, S Monteiro de Almeida, M Ramos, K Abra˜o, L E Madaloso, R L Pinheiro, L C Werneck ............................................................................................................................... J Clin Pathol 2004;57:205–207. doi: 10.1136/jcp.2003.8680 from the usual 15 days to up to 130 days. This type of This report describes a fatal case of central nervous system infection causes granulomata or abscesses and neutrophilic pseudallescheriasis. A 32 year old white man presented with meningitis.125 headache and meningismus 15 days after nearly drowning in a swine sewage reservoir. Computerised tomography and ‘‘In cases secondary to aspiration after near drowning, magnetic resonance imaging of the head revealed multiple once in the bloodstream, fungi seed into several sites but brain granulomata, which vanished when steroid and broad develop mainly in the central nervous system’’ spectrum antimicrobial and antifungal agents, in addition to dexamethasone, were started. Cerebrospinal fluid analysis To date, few cases of CNS pseudallescheriasis have been 2 disclosed a neutrophilic meningitis. Treatment with antibiotics described. However, such a diagnosis must should always be sought in individuals who have suffered near drowning in and amphotericin B, together with fluconazole and later standing polluted streams, ponds of water or sewage, or pits itraconazole, was ineffective. Miconazole was added with manure. through an Ommaya reservoir, but was insufficient to halt The case of a man who acquired a CNS P boydii infection the infection.
    [Show full text]
  • Adverse Events After Immunisation- Common and Uncommon
    Adverse events following Immunisation Common and Uncommon Dr Anna Clarke National Immunisation Office September 2016 www.immunisation.ie Abbreviations • ADR-adverse drug reaction • AE- adverse event • AEFI-adverse event following immunisation • SAE- serious adverse event • SUSAR-suspected unexpected serious adverse reaction Definitions • Adverse Drug Reaction – A response to a drug which is noxious and unintended, …occurs at doses normally used for the prophylaxis,.. or therapy of disease, … • Adverse Event – Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment Definitions Adverse Event Following Immunization (AEFI) Any untoward medical occurrence which follows immunisation and which does not necessarily have a causal relationship with the usage of the vaccine. The adverse event may be any unfavourable or unintended sign, abnormal laboratory finding, symptom or disease. AEFI 1. Loose definition to encourage reporting - does not restrict type of event - does not limit the time after immunisation - events, not reactions, are reported 2. Belief that immunisation was responsible may be correct, incorrect, or impossible to assess 3. Does not imply causality AEFIs Mild Reactions – Common – Include pain, swelling, fever, irritability, malaise – Self-limiting, seldom requiring symptomatic treatment But - important to inform parents about such events so they know about them Serious Adverse Event • Fatal • Life-threatening •
    [Show full text]
  • Reviewer Guidance
    Reviewer Guidance Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2005 Good Review Practices Reviewer Guidance Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review Additional copies are available from: Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2005 Good Review Practices TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. GENERAL GUIDANCE ON THE CLINICAL SAFETY REVIEW .......................... 2 A. Introduction....................................................................................................................................2 B. Explanation of Terms ....................................................................................................................3 C. Overview of the Safety Review .....................................................................................................4 D. Differences in Approach to Safety and Effectiveness Data ........................................................4
    [Show full text]
  • AHRQ Quality Indicators Fact Sheet
    AHRQ Quality Indicators Toolkit Fact Sheet on Inpatient Quality Indicators What are the Inpatient Quality Indicators? The Inpatient Quality Indicators (IQIs) include 28 provider-level indicators established by the Agency for Healthcare Research and Quality (AHRQ) that can be used with hospital inpatient discharge data to provide a perspective on quality. They are grouped into the following four sets: • Volume indicators are proxy, or indirect, measures of quality based on counts of admissions during which certain intensive, high-technology, or highly complex procedures were performed. They are based on evidence suggesting that hospitals performing more of these procedures may have better outcomes. • Mortality indicators for inpatient procedures include procedures for which mortality has been shown to vary across institutions and for which there is evidence that high mortality may be associated with poorer quality of care. • Mortality indicators for inpatient conditions include conditions for which mortality has been shown to vary substantially across institutions and for which evidence suggests that high mortality may be associated with deficiencies in the quality of care. • Utilization indicators examine procedures whose use varies significantly across hospitals and for which questions have been raised about overuse, underuse, or misuse. Mortality for Selected Procedures and Mortality for Selected Conditions are composite measures that AHRQ established in 2008. Each composite is estimated as a weighted average, across a set of IQIs, of the ratio of a hospital’s observed rate (OR) to its expected rate (ER), based on a reference population: OR/ER. The IQI-specific ratios are adjusted for reliability before they are averaged, to minimize the influence of ratios that are high or low at a specific hospital by chance.
    [Show full text]
  • Interventions for Treating Acute High Altitude Illness
    This document is downloaded from DR‑NTU (https://dr.ntu.edu.sg) Nanyang Technological University, Singapore. Interventions for treating acute high altitude illness Simancas‑Racines, Daniel; Arevalo‑Rodriguez, Ingrid; Osorio, Dimelza; Franco, Juan V.A.; Xu, Yihan; Hidalgo, Ricardo 2018 Simancas‑Racines, D., Arevalo‑Rodriguez, I., Osorio, D., Franco, J. V., Xu, Y., & Hidalgo, R. Interventions for treating acute high altitude illness. Cochrane Database of Systematic Reviews. (6), CD009567‑. doi:10.1002/14651858.CD009567.pub2 https://hdl.handle.net/10356/82999 https://doi.org/10.1002/14651858.CD009567.pub2 © 2018 The Cochrane Collaboration. All rights reserved. This paper was published by John Wiley & Sons, Ltd. in Cochrane Database of Systematic Reviews and is made available with permission of The Cochrane Collaboration. Downloaded on 28 Sep 2021 20:37:23 SGT [Intervention Review] Interventions for treating acute high altitude illness Daniel Simancas-Racines1, Ingrid Arevalo-Rodriguez1,2,3, Dimelza Osorio1, Juan VA Franco4, Yihan Xu5, Ricardo Hidalgo1 1Cochrane Ecuador. Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador. 2Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain. 3CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 4Argentine Cochrane Centre, Instituto Universi- tario Hospital Italiano, Buenos Aires, Argentina. 5Wee Kim Wee School of Communication and Information, Nanyang Technological University, Singapore City, Singapore Contact address: Daniel Simancas-Racines, Cochrane Ecuador. Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador. [email protected], [email protected].
    [Show full text]
  • Regulation of High-Altitude Hypoxia on the Transcription of CYP450 and UGT1A1 Mediated by PXR and CAR
    ORIGINAL RESEARCH published: 17 September 2020 doi: 10.3389/fphar.2020.574176 Regulation of High-Altitude Hypoxia on the Transcription of CYP450 and UGT1A1 Mediated by PXR and CAR † † Ya-bin Duan 1,2 , Jun-bo Zhu 1,2 , Jian-xin Yang 2, Gui-qin Liu 3, Xue Bai 1, Ning Qu 4*, Xue-jun Wang 5* and Xiang-yang Li 2* Edited by: 1 Research Center for High Altitude Medicine, Qinghai University Medical College, Xining, China, 2 State Key Laboratory of Yurong Lai, Plateau Ecology and Agriculture, Qinghai University, Xining, China, 3 College of Eco-Environmental Engineering, Qinghai Gilead, United States University, Xining, China, 4 Department of Anesthesiology, Qinghai Hospital of Traditional Chinese Medicine, Xining, China, 5 Reviewed by: Department of Anesthesiology, Red Cross Hospital of Qinghai, Xining, China Cindy Yanfei Li, Amgen, United States Little is known about what roles the pregnane X receptor (PXR) and constitutive Xavier Decleves, Universite´ Paris Descartes, France androstane receptor (CAR) play in drug metabolism in high-altitude hypoxia. Likewise, *Correspondence: the potential interaction of nuclear receptors and drug metabolism enzymes during drug Ning Qu metabolism of high-altitude hypoxia is not fully understood. In this work, we investigated [email protected] Xue-jun Wang the effects of high-altitude hypoxia on transcriptional regulation of cytochrome P450 [email protected] (CYP450) and UDP-glucuronosyltransferase 1A1 (UGT1A1) genes mediated by PXR and Xiang-yang Li CAR proteins. The protein and mRNA expressions of CYP450, UGT1A1, PXR, and CAR [email protected] were determined by enzyme-linked immunosorbent assay and qPCR in rats and HepG2 †These authors share first authorship cell lines under hypoxia.
    [Show full text]
  • Reporting Adverse Drug Reactions
    CIOMS ORGANIZATIONS1949 OF MEDICAL SCIENCES COUNCIL FOR INTERNATIONAL REPORTING ADVERSE 1999 REPORTING ADVERSE DRUG REACTIONS DRUG ADVERSE REPORTING DRUG REACTIONS DEFINITIONS OF TERMS AND CRITERIA FOR THEIR USE DEFINITIONS OF TERMS AND CRITERIA FOR THEIR USE TERMS AND CRITERIA FOR DEFINITIONS OF CIOMS publications may be obtained direct from CIOMS, c/o World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland. They are also distributed by the World Health Organization, Distribution and Sales Unit, Avenue Appia, 1211 Geneva 27, Switzerland and are available from booksellers through the network of WHO sales agents. A list of these agents may be obtained by writing to the above address. Price: SF 35.-- (including CD-ROM) REPORTING ADVERSE DRUG REACTIONS Definitions of Terms and Criteria for their Use Geneva Book and CD--Rom Copyright # 1999 by the Council for International Organizations of Medical Sciences (CIOMS) ISBN 92 9036 071 2 Printed in Switzerland Reprinted 2000 EDITORIAL GROUP Z. Bankowski R. Bruppacher I. Crusius J. Gallagher G. Kremer J. Venulet The Council for International Organizations of Medical Sciences (CIOMS) is a nongovernmental organization established jointly by the World Health Organization and UNESCO in 1949, with a mandate to collaborate with the United Nations and its specialized agencies. Its international membership, consisting of international unions and federations of national associations and societies, represents a substantial proportion of the world’s biomedical scientific community. Its secretariat is located in Geneva in offices made available by the World Health Organization. A dominant theme of CIOMS for some time has been the ethical aspects of biomedical technology and the bioethical considerations to be taken into account in determining and implementing health policy.
    [Show full text]
  • Adverse Drug Reaction Reporting
    P T Chapter 40 Adverse Drug Reaction Reporting Lee B. Murdaugh, RPh, PhD The Conditions of Participation standards of the Centers for Medicare & Medicaid Services (CMS) and the standards of accrediting organizations such as The Joint Commission, the Healthcare Facilities Accredi- tation Program (HFAP), and the National Integrated Accreditation for Healthcare Organizations (NIAHOSM) require hospitals to identify and report adverse drug reactions (ADRs). These ADRs must be reported to LEARNING OBJECTIVES patients’ attending physicians and the hospital’s quality assessment and performance improvement program. Additionally, hospitals are expected to report serious • Define an adverse drug reaction. ADRs (as defined by the Food and Drug Administration • Discuss the detection of adverse [FDA]) to the FDA’s MedWatch program and ADRs to vaccines to the FDA’s Vaccine Adverse Events Reporting drug reactions. System (VAERS). • Discuss the assessment of adverse drug reactions. Defining Adverse Drug Reactions To recognize and assess ADRs, there must be a defini- tion of what constitutes an ADR. Examples of commonly used definitions are discussed in the following text. The FDA defines a serious adverse reaction as one in which “the patient outcome is death, life threat- ening (real risk of dying), hospitalization (initial or prolonged), disability (significant, persistent, or perma- nent), congenital anomaly, or required intervention to prevent permanent impairment or damage.”1 The American Society of Health-System Pharma- cists (ASHP) defines a ADR as “any unexpected, unin- tended, undesired, or excessive response to a drug that • requires discontinuing the drug (therapeutic or diagnostic) • requires changing the drug therapy • requires modifying the dose (except for minor dosage adjustments) • necessitates admission to a hospital 546 Competence Assessment Tools for Health-System Pharmacies • prolongs stay in a healthcare facility routine observation and assessment.
    [Show full text]
  • Adverse Drug Reactions – Allergy? Side-Effect? Intolerance?
    Medications Adverse drug reactions Allergy? Side-effect? Intolerance? William Smith Background There are two common situations that require assessment Adverse drug reactions (ADRs) vary from life-threatening of adverse drug reactions (ADRs): anaphylaxis to minor common side-effects. • Current reaction: a patient develops new symptoms while taking a particular drug. Is the drug the cause of the Objective symptoms and if so, should it be stopped? To provide an overview on the assessment of ADRs. To discuss the features of what may be described as a ‘reaction • Previous reaction: in the recent or distant past; often the to a drug’ in order to highlight those suggestive of allergy, patient’s recall is poor and information is lacking. Can the side-effect or intolerance, and what implications this might drug be used again? have for the future use or avoidance of the drug. In the setting of a current reaction, it is important to make a thorough Discussion assessment of the nature and severity of the ADR, and where not Assessment of an ADR may apply to a current reaction or a history of a past reaction. The main decision is whether to obvious, refer to available information on the known side-effects of cease the drug and/or whether it can be used again. Some the medication in question. Where allergy is suspected, testing may ADRs are serious and likely to be reproducible and constitute be helpful. For example, serum tryptase in the case of suspected absolute contraindications, whereas others are mild and may anaphylaxis, eosinophilia in a chronic reaction, and skin biopsy in or may not occur on subsequent exposure.
    [Show full text]
  • Study Protocol
    Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Study Title Healthy Adults NCT Number NCT03828149 Document Description Clinical Protocol, Version: V04_0 Document Date 08 Jan 2019 TRIAL PROTOCOL EVALUATION OF SAFETY AND PHARMACODYNAMICS OF OP0201 COMPARED TO PLACEBO IN HEALTHY ADULTS Novus Therapeutics, Inc. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 19900 MacArthur Blvd., Suite 550 xxxxxxxxxxxxxxxxxxxxxxxxxxxxx Irvine, California 92612, U.S.A. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (Sponsor) xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx represented by xxxxxxxxxxxxxxxxxxxxxxxxxxx University of Cologne xxxxxxxxxxxxxxxxxxx Albertus-Magnus-Platz xxxxxxxxxxxxx 50923 Cologne Germany xxxxxxx (EU Sponsor Representative) Novus TherapeuticsTrial Protocol Code: OP0201-C001 University of Cologne Internal Trial Protocol Code: Uni-Koeln-2809 EudraCT number: 2016-003667-19 08-01-2018, Version V04_0 The information in this trial protocol is strictly confidential. It is for the use of the Sponsor, investigator, trial personnel, ethics committee, the authorities, and trial subjects only. This trial protocol may not be passed on to third parties without the express agreement of the Sponsor or the Principal Coordinating Investigator (PCI, “Leiter der klinischen Prüfung (LKP)”). Trial protocol V04_0 of 08-01-2018 Novus Therapeutics, Inc. by University of Cologne OP0201-C001 Page 2 of 66 I. Signatures xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Signature Date xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx
    [Show full text]
  • NCCMERP Fact Sheet 2015-02-V9.Indd
    Questions About NCC MERP and Medication Errors Shawn C. Becker, M.S., B.S.N., Director Healthcare Quality Standards, Science and Standards Division [email protected] / (301) 816–8216 tel / (301) 816-8532 fax Contemporary View of Medication– Related Harm. A New Paradigm Introduction Scenario/Case Studies The NCC MERP has frequently been asked to help healthcare Medication error resulting in no harm professionals distinguish among Adverse Drug Events (ADEs), Case 1. A 25 kg child with no prior history of penicillin allergy was Adverse Drug Reactions (ADRs) and Medication Errors. The Council prescribed 250 mg orally of amoxicillin suspension twice daily notes several defi nitions for these terms in the literature, research (morning and evening) for 7 days. On the seventh day, the child reports, and by various organizations. The terms ADE and ADR inadvertently received a morning dose of 500 mg instead of 250 mg. have been used when patient harm has occurred as a result of a The child did not suff er any negative consequences from the error. drug (see defi nitions). To further clarify, an ADR has been defi ned as harm that results from a medication dose that is “normally used in A preventable ADE (medication-related harm due to error) man.” An ADE has been defi ned as harm associated with any dose Case 2. A 74 year old female with acute leg pain presented to of a drug, whether the dose is “normally used in man” or not. An the emergency department. She has a history of sleep apnea. ADR, therefore, is a subtype of an ADE (i.e., all ADRs are ADEs, but She has no previous history of opioid use.
    [Show full text]
  • Adverse Drug Reaction Questionnaire
    Name: ______________________ Date: ______________________ ADVERSE DRUG REACTION QUESTIONNAIRE Demographic Data Name: _____________________________ DOB: ________________ Date: ________________ Address: ______________________________________________________________________ Telephone: Home___________________________________ Work: ___________________________________ Cell: ____________________________________ Emergency Contact: _____________________________________________________________ Relation: ______________________________________________________________________ Address: ______________________________________________________________________ Telephone: ______________________________ Referring Physician: _____________________________________________________________ Address: ______________________________________________________________________ Telephone: _____________________________ 1 Name: ______________________ Date: ______________________ Allergy History Chief Complaint: What Medication caused your reaction? ______________________________________________________________________________________ Why were you receiving this medication? ______________________________________________________________________________________ When did you receive this medication? ________________________________________________________________________________________ How many times have you received this medication? _____________________________________________________________________________ Do you receive other medications with or just before this medication?
    [Show full text]